Breast Cancer Research - oalib

OALib Journal期刊
ISSN: 2333-9721
费用：99美元

投递稿件

为什么选择我们？ >>

- 开源期刊

- 同行审议

- 快速出刊

- 终身存储

- 免费检索

- 免费推广

- 更多...

- 搜索引擎

Breast Cancer Research

ISSN Print: 1465-5411

ISSN Online:

主页: http://breast-cancer-research.com

分享:

Breast cancer proteomics reveals correlation between estrogen receptor status and differential phosphorylation of PGRMC1

Hans Neubauer, Susan E Clare, Wojciech Wozny, Gerhard P Schwall, Slobodan Poznanovi？, Werner Stegmann, Ulrich Vogel, Karl Sotlar, Diethelm Wallwiener, Raffael Kurek, Tanja Fehm, Michael A Cahill

TIMP-2 mediates the anti-invasive effects of the nitric oxide-releasing prodrug JS-K in breast cancer cells

Ann-Marie Simeone, Vanity McMurtry, René Nieves-Alicea, Joseph E Saavedra, Larry K Keefer, Marcella M Johnson, Ana M Tari

Wnt signalling in human breast cancer: expression of the putative Wnt inhibitor Dickkopf-3 (DKK3) is frequently suppressed by promoter hypermethylation in mammary tumours

Jürgen Veeck, Nuran Bektas, Arndt Hartmann, Glen Kristiansen, Uwe Heindrichs, Ruth Knüchel, Edgar Dahl

Serial analysis of gene expression of lobular carcinoma in situ identifies down regulation of claudin 4 and overexpression of matrix metalloproteinase 9

Dengfeng Cao, Kornelia Polyak, Marc K Halushka, Hind Nassar, Nina Kouprina, Christine Iacobuzio-Donahue, Xinyan Wu, Saraswati Sukumar, Jessica Hicks, Angelo De Marzo, Pedram Argani

Prospective study of physical activity and risk of postmenopausal breast cancer

Michael F Leitzmann, Steven C Moore, Tricia M Peters, James V Lacey, Arthur Schatzkin, Catherine Schairer, Louise A Brinton, Demetrius Albanes

Novel image analysis approach for quantifying expression of nuclear proteins assessed by immunohistochemistry: application to measurement of oestrogen and progesterone receptor levels in breast cancer

Elton Rexhepaj, Donal J Brennan, Peter Holloway, Elaine W Kay, Amanda H McCann, Goran Landberg, Michael J Duffy, Karin Jirstrom, William M Gallagher

Serum biomarker profiles and response to neoadjuvant chemotherapy for locally advanced breast cancer

Brian M Nolen, Jeffrey R Marks, Shlomo Ta'san, Alex Rand, The Luong, Yun Wang, Kimberly Blackwell, Anna E Lokshin

Correction: Decline in breast cancer incidence due to removal of promoter: combination estrogen plus progestin

Graham A Colditz

The promise and limitations of genome-wide association studies to elucidate the causes of breast cancer

Christine B Ambrosone

Risk factors for breast cancer characterized by the estrogen receptor alpha A908G (K303R) mutation

Kathleen Conway, Eloise Parrish, Sharon N Edmiston, Dawn Tolbert, Chiu-Kit Tse, Patricia Moorman, Beth Newman, Robert C Millikan

HER2 therapy. Small molecule HER-2 tyrosine kinase inhibitors

Neil Spector, Wenle Xia, Iman El-Hariry, Yossi Yarden, Sarah Bacus

Inhibitory effects of estrogen receptor beta on specific hormone-responsive gene expression and association with disease outcome in primary breast cancer

Chin-Yo Lin, Anders Str？m, Say Li Kong, Silke Kietz, Jane S Thomsen, Jason BS Tee, Vinsensius B Vega, Lance D Miller, Johanna Smeds, Jonas Bergh, Jan-？ke Gustafsson, Edison T Liu

Obesity hormone leptin: a new target in breast cancer?

Eva Surmacz

Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients

Lisa K Dunnwald, Mary Rossing, Christopher I Li

Assessing prognosis for early breast cancer: clinical versus genetic profiles

GN Hortobagyi

Circulating tumor and endothelial cells as predictors of response in metastatic breast cancer

M Cristofanilli

Induction of epithelial to mesenchymal transition in PMC42-LA human breast carcinoma cells by carcinoma-associated fibroblast secreted factors

Stephanie C Lebret, Donald F Newgreen, Erik W Thompson, M Leigh Ackland

The dangers of complementary therapy

Mike Baum

Telomeric DNA induces apoptosis and senescence of human breast carcinoma cells

Mina Yaar, Mark S Eller, Izabela Panova, John Kubera, Lee Wee, Kenneth H Cowan, Barbara A Gilchrest

Standards and future strategies in adjuvant chemotherapy treatments

C Hudis, H McArthur

Present and future role of bisphosphonates in treatment

GN Hortobagyi

Preoperative systemic treatment for operable disease: biological correlates of response to neoadjuvant treatment

GN Hortobagyi

Adjuvant hormonal therapy for postmenopausal women

EP Winer

Current status of adjuvant endocrine therapy for premenopausal patients with primary breast cancer

A Howell

Treatment of metastatic disease after current adjuvant approaches (taxanes, aromatase inhibitors, trastuzumab)

PF Conte, V Guarneri, C Bengala

Molecular and gene expression-based predictors of response to preoperative chemotherapy

L Pusztai

Characterization of a negative transcriptional element in the BRCA1 promoter

Gwen MacDonald, Melissa Stramwasser, Christopher R Mueller

Adenovirus type 5 E1A-induced apoptosis in COX-2-overexpressing breast cancer cells

Takeshi Sugimoto, Chandra Bartholomeusz, Ana M Tari, Naoto T Ueno

Dietary intake and breast density in high-risk women: a cross-sectional study

Marilyn Tseng, Celia Byrne, Kathryn A Evers, Mary B Daly

Live or let die: oestrogen regulation of survival signalling in endocrine response

Alison J Butt, Robert L Sutherland, Elizabeth A Musgrove

Epidermal growth factor receptor (EGFR) is transcriptionally induced by the Y-box binding protein-1 (YB-1) and can be inhibited with Iressa in basal-like breast cancer, providing a potential target for therapy

Anna L Stratford, Golareh Habibi, Arezoo Astanehe, Helen Jiang, Kaiji Hu, Eugene Park, Ashleen Shadeo, Timon PH Buys, Wan Lam, Trevor Pugh, Marco Marra, Torsten O Nielsen, Uwe Klinge, Peter R Mertens, Samuel Aparicio, Sandra E Dunn

Regulator of G-protein signalling 2 mRNA is differentially expressed in mammary epithelial subpopulations and over-expressed in the majority of breast cancers

Matthew J Smalley, Marjan Iravani, Maria Leao, Anita Grigoriadis, Howard Kendrick, Tim Dexter, Kerry Fenwick, Joseph L Regan, Kara Britt, Sarah McDonald, Christopher J Lord, Alan MacKay, Alan Ashworth

Signal transducer and activator of transcription 5b: a new target of breast tumor kinase/protein tyrosine kinase 6

Amanda M Weaver, Corinne M Silva

Stat3 is tyrosine-phosphorylated through the interleukin-6/glycoprotein 130/Janus kinase pathway in breast cancer

Marjan Berishaj, Sizhi Gao, Simi Ahmed, Kenneth Leslie, Hikmat Al-Ahmadie, William L Gerald, William Bornmann, Jacqueline F Bromberg

Cooperation between Wnt and Notch signalling in human breast cancer

Giovanna M Collu, Keith Brennan

BCoR-L1 variation and breast cancer

Felicity Lose, Jeremy Arnold, David B Young, Carolyn J Brown, Graham J Mann, Gulietta M Pupo, The Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer, Kum Khanna, Georgia Chenevix-Trench, Amanda B Spurdle

Application of the multicellular tumour spheroid model to screen PET tracers for analysis of early response of chemotherapy in breast cancer

Azita Monazzam, Raymond Josephsson, Carl Blomqvist, J？rgen Carlsson, Bengt L？ngstr？m, Mats Bergstr？m

The effect of psychosocial factors on breast cancer outcome: a systematic review

Matthew E Falagas, Effie A Zarkadoulia, Eleni N Ioannidou, George Peppas, Christos Christodoulou, Petros I Rafailidis

The zinc finger domain of Wilms' tumor 1 suppressor gene (WT1) behaves as a dominant negative, leading to abrogation of WT1 oncogenic potential in breast cancer cells

Youqi Han, Serban San-Marina, Lin Yang, Haytham Khoury, Mark D Minden

Inflammation and breast cancer. Inflammatory component of mammary carcinogenesis in ErbB2 transgenic mice

Raffaele Calogero, Francesca Cordero, Guido Forni, Federica Cavallo

Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal women

Paul E Goss, Peyman Hadji, Milayna Subar, Paula Abreu, Torben Thomsen, Jose Banke-Bochita

GnRH and LHR gene variants predict adverse outcome in premenopausal breast cancer patients

Djura Piersma, Axel PN Themmen, Maxime P Look, Jan GM Klijn, John A Foekens, André G Uitterlinden, Huibert AP Pols, Els MJJ Berns

Heregulin β1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells

Iain R Hutcheson, Janice M Knowlden, Steve E Hiscox, Denise Barrow, Julia MW Gee, John F Robertson, Ian O Ellis, Robert I Nicholson

The effect of versican G3 domain on local breast cancer invasiveness and bony metastasis

Albert JM Yee, Margarete Akens, Bing L Yang, Joel Finkelstein, Peng-Sheng Zheng, Zhaoqiong Deng, Burton Yang

HER2 therapy. HER2 (ERBB2): functional diversity from structurally conserved building blocks

Ralf Landgraf

Intrinsic genetic characteristics determine tumor-modifying capacity of fibroblasts: matrix metalloproteinase-3 5A/5A genotype enhances breast cancer cell invasion

Deborah L Holliday, Simon Hughes, Jacqueline A Shaw, Rosemary A Walker, J Louise Jones

Common variants in the ATM, BRCA1, BRCA2, CHEK2 and TP53 cancer susceptibility genes are unlikely to increase breast cancer risk

Caroline Baynes, Catherine S Healey, Karen A Pooley, Serena Scollen, Robert N Luben, Deborah J Thompson, Paul DP Pharoah, Douglas F Easton, Bruce AJ Ponder, Alison M Dunning, the SEARCH breast cancer study

Decline in breast cancer incidence due to removal of promoter: combination estrogen plus progestin

Graham A Colditz

Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status

Tanja Fehm, Sven Becker, Silke Duerr-Stoerzer, Karl Sotlar, Volkmar Mueller, Diethelm Wallwiener, Nancy Lane, Erich Solomayer, Jonathan Uhr

Efficacy of adjuvant chemotherapy according to hormone receptor status in young patients with breast cancer: a pooled analysis

Jos A van der Hage, J Mieog, Marc J van de Vijver, Cornelis JH van de Velde, cooperating investigators of the European Organization for Research and Treatment of Cancer

©2008-2020 OALib, Inc | Public user content licensed CC-BY 4.0 unless otherwise specified. OALib ISSN Online: 2333-9721 OALib ISSN Print: 2333-9705